Document is current
Any future updates will be listed below
-
Authors
de Groen, Ruben A. L. https://orcid.org/0000-0002-2998-2066
de Groot, Fleur A.
Böhringer, Stefan
Kret, Esther J. https://orcid.org/0000-0001-9485-1786
de Haan, Lorraine M.
Noordenbos, Troy
Blommers, Susan
Jansen, Romée E. W.
van Wezel, Tom https://orcid.org/0000-0001-5773-7730
van Eijk, Ronald
Raghoo, Richard
Ruano, Dina
Boome, Liane te
Terpstra, Valeska
Levenga, Henriette
Ahsmann, Els
Posthuma, Eduardus F. M.
Focke-Snieders, Isabelle
Hardi, Lizan
den Hartog, Wietske C. E.
van den Berg, Anke https://orcid.org/0000-0002-8894-2638
Mutsaers, Pim
Lam, King https://orcid.org/0000-0003-3903-1085
van der Poel, Marjolein W. M.
Hamid, Myrurgia Abdul
Woei-A-Jin, F. J. Sherida H. https://orcid.org/0000-0001-7840-6156
Janssens, Ann
Tousseyn, Thomas https://orcid.org/0000-0002-0397-1086
Bovée, Judith V. M. G.
Koens, Lianne
Diepstra, Arjan https://orcid.org/0000-0001-9239-1050
Cleven, Arjen H. G.
Kersten, Marie José https://orcid.org/0000-0002-8904-3802
Jansen, Patty M.
Veelken, Hendrik https://orcid.org/0000-0002-9108-3125
Nijland, Marcel https://orcid.org/0000-0002-2740-2873
Dekker, Tim J. A.
Vermaat, Joost S. P. https://orcid.org/0000-0002-1628-6256
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 14 April 2025
Accepted: 17 April 2025
First Online: 29 April 2025
Competing interests
: A.D. received research funding from and participated in advisory board of Takeda. F.J.S.H.W.-A-J. participated in educational event from Takeda and participated in advisory board of Recordati. M.J.K. has received honoraria from and performed a consulting/advisory role for Celgene subsidiary of Bristol Myers Squibb, Kite subsidiary of Gilead, Miltenyi Biotec, Novartis, Adicet Bio, and Roche; research funding from Kite (Gilead), Roche, Takeda and Celgene (BMS); and travel support from Kite (Gilead), Miltenyi Biotec, Novartis, Abbvie, and Roche. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene (BMS), Incyte, and Regeneron. The remaining authors declare no competing (financial) interests.
